SUDA GOKI

スダゴウキ | SUDA GOKI

Affiliation and department：
Homepage URL (1)： http://kaken.nii.ac.jp/d/r/20447460.ja.html

Research field (1)： Gastroenterology

Research theme for competitive and other funds (18)：

2022 - 2025 肝線維化治療標的同定とそれに基づく新規抗肝線維化治療法開発
2022 - 2025 PARP inhibitor resistance in cancer stem cells in hepatocelular carcinoma
2022 - 2025 食道扁平上皮癌がん幹細胞における免疫逃避機構の解明
2022 - 2025 Comprehensive search for host factors related to liver fibrosis mechanisms and development of novel therapeutic strategies
2021 - 2024 肝癌幹細胞の維持・免疫寛容機構の解明と治療最適化の検討

Show all

Papers (209)：

Margherita Rimini, Bernardo Stefanini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Fabian Finkelmeier, Changhoon Yoo, José Presa, Elisabeth Amadeo, et al. Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab. Liver international : official journal of the International Association for the Study of the Liver. 2024
Silvia Camera, Margherita Rimini, Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, et al. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma. Targeted oncology. 2024
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, et al. α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. International journal of cancer. 2023
Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Akio Ido, Hidekatsu Kuroda, Daiki Miki, Masayuki Kurosaki, Yoichi Hiasa, Ryotaro Sakamori, et al. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus. Journal of gastroenterology. 2023
荘拓也, 須田剛生, 北潟谷隆, 大原正嗣, 中井正人, 小川浩司, 坂本直哉. 【薬物療法によって変貌する肝細胞癌治療:2023 Update】Advanced stage肝細胞癌 Phase 3 HIMALAYA試験の結果とその解釈. 肝胆膵. 2023. 87. 4. 439-446

ｍore...

MISC (243)：

中村昭伸, 大江悠希, 久住麻唯子, 宮愛香, 野本博司, 亀田啓, 曹圭龍, 小川浩司, 荘拓也, 須田剛生, et al. 減量・代謝改善手術後の膵β細胞機能改善に肝の脂肪化が関連する. 糖尿病. 2022. 65. Suppl.1. S-153
大原正嗣, 須田剛生, 重沢拓, 鈴木和治, 中村晃久, 川岸直樹, 中井正人, 荘拓也, 森川賢一, 小川浩司, et al. 肝疾患患者における筋肉量の経時変化の評価はBIA法に比べCT画像を用いた方法が有用である. 肝臓. 2021. 62. Supplement 1
須田剛生, 大原正嗣, 坂本直哉. 日本人におけるpsoas muscle mass index最適cut-off値の検討と肝疾患患者における検討. 日本消化器病学会雑誌(Web). 2021. 118
小川浩司, 中井正人, 荘拓也, 須田剛生, 森川賢一, 坂本直哉. Intrahepatic arterio-venous shunt. 日本臨床. 2021
中井正人, 北潟谷隆, 山田錬, 重沢拓, 鈴木和治, 中村晃久, 梅村真知子, 荘拓也, 須田剛生, 森川賢一, et al. トルバプタン奏効後の再燃と炎症および尿L-FABP値の関連. 肝臓. 2020. 61. Supplement 1

ｍore...

Lectures and oral presentations (242)：

減量・代謝改善手術後の膵β細胞機能改善に肝の脂肪化が関連する
(糖尿病 2022)
日本人におけるpsoas muscle mass index最適cut-off値の検討と肝疾患患者における検討
(日本消化器病学会雑誌(Web) 2021)
Intrahepatic arterio-venous shunt
(日本臨床 2021)
肝疾患患者における筋肉量の経時変化の評価はBIA法に比べCT画像を用いた方法が有用である
(肝臓 2021)
Comparative Glycomic Analysis by Aminolysis-SALSA method combined with Sialyl Linkage-specific Isotope Labeling.
(日本糖質学会年会要旨集 2020)

ｍore...

Professional career (1)：

医学博士 (東京医科歯科大学)

Work history (1)：

2013 - Hokkaido University

Awards (12)：

2022 - The 31st Conference of the Asian Pacific Association for Study of the liver (APASL) Travel Award.
2021 - APDWF-JGHF Emerging Leader Award
2020 - 寿原記念財団研究助成
2019 - The 3rd Joint Session between TDDW-JDDW-KDDW Rising Star Award
2019 - Journal of Gastroenterology High Citation Award

Show all

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page